Accelus closed a $20 million debt facility from Symbiotic Capital, according to a Jan. 18 news release.
The funding will help support Accelus' focus on its Adaptive Geometry for th FlareHawk interbody fusion system with additional clinical studies, the release said. The company also plans to use the money to expand its reach into new markets.
"Symbiotic Capital is an ideal partner for Accelus, sharing our commitment to innovations that support surgeons and improve patient outcomes, and their support will be instrumental in broadening our market reach and speeding up our R&D to ensure we stay at the forefront of spinal implant technology," Kevin McGann, president and CEO of Accelus, said in the release.